Objective:
Nonacog beta pegol (N9-GP) and recombinant factor IX-Fc fusion protein (rFIXFc) are two modified rFIX compounds with extended half-lives compared with standard FIX products. We report results from two head-to-head,…
From University of Texas Health Science Center at Tyler (UTHSCT). Dr. Magisetty completed Ph.D. doctoral training on the evaluation of FVIIa-EPCR interactions in the management of hemophilic arthropathy and is enthusiastic looking forward to the…
I am currently working as a Postdoctoral Research Associate at the University of Texas Health Science Center at Tyler, Tyler, Texas, under the mentorship of Professor L. Vijaya Mohan Rao. My research focuses on elucidating novel mechanisms by which…
NHF’s Annual Bleeding Disorders Conference (BDC) is our signature event and highlights our strong commitment to education. Leading community members and experts on hemophilia and other bleeding disorders come together every year to…
Dear Community,
Not a big surprise that the turning of the page in the calendar did not make all our worries go away. The big stories that consumed our thoughts at the end of last year—the election, the pandemic, and racial inequity—carried…
As we look ahead into the new year, and the changes it will bring, I’ve been reflecting on the importance of the events of 2020 and what we have learned. This past year, tumultuous and strange as it was, has taught us all some lessons that will…
The National Hemophilia Foundation has created a new research fellowship that seeks to create greater diversity in the field of benign hematology with the Jeanne M. Lusher Diversity Fellowship (JML). The fellowship, which hopes to foster career-long…
The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) have developed joint clinical practice guidelines on the…